Nottingham, UK, February 16, 2012 / B3C newswire / - Critical Pharmaceuticals, an emerging biotechnology company, and The University of Nottingham today announce a £545,000 collaboration to develop a nano-enabled intranasal formulation of teriparatide for the treatment of osteoporosis. Osteoporosis affects an estimated 75 million people in Europe, US and Japan with more than 180,000 patients suffer fragility fractures in the UK alone each year, at a cost of around £2 billion to the NHS.
Teriparatide, an excellent recent addition to the range of drugs used for the treatment of osteoporosis, but it currently needs to be injected every day. Our consortium will exploit a recent discovery in nanotechnology to develop a nasal spray formulation of teriparatide that is easy to administer by patients and provides optimal drug plasma levels to enhance efficacy.
The Technology Strategy Board and the Engineering and Physical Sciences Research Council (EPSRC) are supporting this project with grant funding as part of their investment in nanoscale technology-enabled solutions in healthcare.
Critical Pharmaceuticals CriticalSorb™ nanotechnology is a best in class absorption promoter that enables the nasal delivery of biological and challenging small molecule drugs. Biological drugs represent a $100 billion market, and yet nearly all need to be administered by frequent injection. CriticalSorb™ has the potential to transform the delivery of biological drugs by enabling non-invasive delivery that would be strongly preferred by patients. Critical Pharmaceuticals lead product is a nasal formulation of human growth hormone (CP024) that uses CriticalSorb™ and is currently in phase 1 clinical development.
Dr Gareth King, CEO Critical Pharmaceuticals said “We are excited about working with internationally-recognized clinicians and scientists at The University of Nottingham and Nottingham University Hospitals NHS Trust to rapidly develop this highly innovative formulation of teriparatide and look forward to the day we can offer it as an attractive alternative to daily injection for the many older people living with osteoporosis”.
The University of Nottingham has world-leading capabilities in clinical and basic research in osteoporosis, geriatric care, bone pathophysiology and medical imaging. The use of university expertise for imaging drug deposition and clearance will greatly enhance the development of this formulation. This project will draw on interdisciplinary collaborative research from international experts Dr Richard Pearson (Division of Orthopaedic & Accident Surgery), Professor Alan Perkins (Division of Radiological and Imaging Sciences) and Professor Tahir Masud (Geriatric Medicine).
Dr Richard Pearson, Senior Research Fellow in The University of Nottingham’s Faculty of Medicine and Health Sciences, said “I’m delighted to collaborate on this project that will enable us to further develop the world-leading research and development capability at the University of Nottingham for the evaluation of drugs for osteoporosis and to work closely with Critical Pharmaceuticals scientists on the development of an exciting new therapy for this debilitating disease”.
About Critical Pharmaceuticals
Critical Pharmaceuticals is a Nottingham UK-based biotechnology company developing a pipeline of unique biological drug products utilizing its proprietary drug delivery technologies. These technologies enable the development of sustained release injectable depot and nasal delivery of proteins and peptides and small molecular weight drugs. As well as developing it's own pipeline, Critical Pharmaceuticals works in partnership with other pharmaceutical and biotechnology companies to enhance the delivery of their novel drug products.
About The University of Nottingham
The University of Nottingham, described by The Sunday Times University Guide 2011 as ‘the embodiment of the modern international university’, has award-winning campuses in the United Kingdom, China and Malaysia. It is ranked in the UK's Top 10 and the World's Top 75 universities by the Shanghai Jiao Tong (SJTU) and the QS World University Rankings. It was named ‘the world’s greenest university’ in the UI GreenMetric World University Ranking 2011, a league table of the most environmentally-friendly higher education institutions.
The University is committed to providing a truly international education for its 40,000 students, producing world-leading research and benefiting the communities around its campuses in the UK and Asia. Impact: The Nottingham Campaign, its biggest ever fund-raising campaign, will deliver the University’s vision to change lives, tackle global issues and shape the future. For more details, visit: www.nottingham.ac.uk/impactcampaign
More than 90 per cent of research at The University of Nottingham is of international quality, according to the most recent Research Assessment Exercise, with almost 60 per cent of all research defined as ‘world-leading’ or ‘internationally excellent’. Research Fortnight analysis of RAE 2008 ranked the University 7th in the UK by research power.
The University’s vision is to be recognised around the world for its signature contributions, especially in global food security, energy & sustainability, health and medical imaging. The University won a Queen’s Award for Higher and Further Education in 2011, for its research on global food security.
More news from the University at: www.nottingham.ac.uk/news
About the Technology Strategy Board
The Technology Strategy Board is a business-led government body which works to create economic growth by ensuring that the UK is a global leader in innovation. Sponsored by the Department for Business, Innovation and Skills (BIS), the Technology Strategy Board brings together business, research and the public sector, supporting and accelerating the development of innovative products and services to meet market needs, tackle major societal challenges and help build the future economy.
Dr Gareth King, CEO
Tel: +44 115 882 0100
Lindsay Brooke, Media Relations Manager
The University of Nottingham
Tel: 0115 951 5751